Dexcom’s FDA Warning Letter Shows Risks Of Driving Margin As Firm Aims To Launch 15-Day Sensor

Approval ‘Not Impacted’ But Significant Work Ahead On Manufacturing Options

 
• By Shubham Singh
That device, which aims to compete with Abbott’s Libre 3 Plus, will be launched in the second half of 2025, Dexcom says.

More from Diabetic Care

More from Medtech Insight